tirzepatide updates today FDA confirms shortage is still over, gives compounders a grace period FDA approval for Zepbound (tirzepatide)

The pivotal SURPASS clinical trial program for type 2 diabetes enrolled over 10,000 participants across multiple international sites, demonstrating tirzepatide's efficacy across a range of baseline characteristics and disease severities

doi: 10.1016/j.ekir.2024.04.028 [DOI] [PMC free article] [PubMed] [Google Scholar] 5.Patel R, Wadid M, Makwana B, et al

Showing 914 Products 293 345 15% off 3.4 (9) 335 395 15% off 4.4 (3100) 129 199 35% off 4.3 (4221) 186 310 40% off 4.5 (6031) 204 340 40% off 4.4 (5202) 292 365 20% off 4.3 (7136) 291 399 27% off 4.2 (11330) 207 399 48% off 4.1 (4290) 212 249 15% off 4 (487) 360 450 20% off 4.3 (1534) 459 499 8% off 3.9 (1102) 628 785 20% off 4.4 (2027)

The trial did not resume

Results are expected in the 2027 to 2028 timeframe